TRDA — Entrada Therapeutics Balance Sheet
0.000.00%
- $423.47m
- $96.63m
- $210.78m
- 58
- 28
- 23
- 28
Annual balance sheet for Entrada Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 39 | 291 | 189 | 352 | 420 |
| Net Total Receivables | — | — | — | 5.88 | 3.68 |
| Prepaid Expenses | |||||
| Total Current Assets | 39.9 | 299 | 210 | 370 | 440 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 3.04 | 6.26 | 33 | 92.7 | 82 |
| Other Long Term Assets | |||||
| Total Assets | 43.5 | 306 | 252 | 469 | 526 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3.36 | 6.72 | 22 | 159 | 39.5 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 3.36 | 7.12 | 39.5 | 227 | 97.6 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 40.2 | 299 | 213 | 242 | 429 |
| Total Liabilities & Shareholders' Equity | 43.5 | 306 | 252 | 469 | 526 |
| Total Common Shares Outstanding |